The Role of Non-Phosphorylated Beta-Catenin in Blood Cancers
Author Information
Author(s): Xu Jinglan, Suzuki Momoko, Niwa Yousuke, Hiraga Junji, Nagasaka Tetsuro, Ito Masafumi, Nakamura Shigeo, Tomita Akihiro, Abe Akihiro, Kiyoi Hitoshi, Kinoshita Tomohiro, Naoe Tomoki
Primary Institution: Nagoya University Graduate School of Medicine
Hypothesis
What is the significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome?
Conclusion
Nuclear non-phosphorylated beta-catenin is associated with poor prognosis in acute myeloid leukaemia and myelodysplastic syndrome.
Supporting Evidence
- Nuclear non-phosphorylated beta-catenin was detected in 40.7% of AML patients.
- Nuclear NPBC expression was associated with specific AML subtypes and poor prognosis.
- Nuclear NPBC+ AML patients had lower complete remission rates.
- Nuclear NPBC was associated with high International Prognostic Scoring System scores in MDS.
Takeaway
This study found that a specific protein in blood cancer cells can help doctors understand how serious the disease is and how to treat it better.
Methodology
The study analyzed bone marrow specimens from patients using immunohistochemistry to detect nuclear non-phosphorylated beta-catenin.
Potential Biases
There may be bias due to the male predominance in the sample population.
Limitations
The study had a small sample size and may not represent all patients with these conditions.
Participant Demographics
The study included 54 patients with acute myeloid leukaemia and 44 patients with myelodysplastic syndrome, with a median age of 53 years for AML and 57 years for MDS.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website